Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses

Abstract

The authors investigated whether the antiatherogenic effects of pravastatin sodium and the antiplatelet effects of aspirin have additive clinical benefits. Meta-analyses were undertaken of the Long-Term Intervention With Pravastatin in lschaemic Disease trial and the Cholesterol and Recurrent Events trial to see if pravastatin and aspirin have additive benefits. Similar additive benefits of pravastatin and aspirin on cardiovascular disease were shown. The relative risk reduction with pravastatin and aspirin was 31% for myocardial infarction compared with aspirin alone and 26% compared with pravastatin alone. The authors concluded that increasing use of the combination to the current level of aspirin use would avoid large numbers of premature death.

Keywords

aspirin pravastatin sodium cardiovascular disease

Get full access to this article

View all access options for this article.

References

1. Long-term Intervention With Pravastatin in ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.

2. Sacks FM , Pfeffer MA , Moye LA , et al, for the Cholesterol and Recurrent Events Trial Investigrators: The effect of pravastatin on coronary events after myocardial Iinfarction in patients with average cholesterol levels. N EngI J Med 335:1001-1019, 1996.

3. Pitt B , Mancini GB , Ellis SG , et al: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 26:1133-1139, 1995.

4. Crouse JR. Byington RP , Bond MG , et al: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-I1). Am J Cardiol 75:455-459, 1995.

5. Jukema JW , Brushka AVG , van Boven AJ , et al. Effects of Lipid Lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels; the Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995.

6. Ridker PM , Rifai N , Pfeffer MA , et al for the Cholesterol and Recurrent Events (CARE) Investigators: inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998.

7. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients: Antithrombotic Trialists' Collaboration (ATT) [published erratum appears in BMJ. 2002; 324:141]. BMJ 324:71-86, 2002.

8. Samson RH : Pharmaceutical initiatives to combat atherosclerosis-what to do with the good, the bad, and the ugly lipoproteins. Semin Vasc Surg 15(4):204-215, 2002

9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ill). JAMA 285:2486-2497, 2001.